Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report
- Shixia Dong
- Kunjing Liu
- Ruijuan Liu
- Jing Zhuang
Affiliations: Clinical Medical Colleges, Weifang Medical University, Weifang, Shandong 261053, P.R. China, College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China, Department of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong 261000, P.R. China
- Published online on: August 8, 2022 https://doi.org/10.3892/etm.2022.11554
Copyright: © Dong
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Immunotherapy through blocking programmed cell death 1, programmed death‑ligand 1 and cytotoxic T lymphocyte antigen 4 is developing rapidly and has gained increasing attention as a treatment for malignant tumors. However, some patients experience varying degrees of immune‑related side effects after undergoing immunotherapy, with hyperprogressive disease (HPD) occurring in severe cases which increases the risk of mortality. The present study discussed the risk factors for HPD following immunotherapy in a case of lung squamous cell carcinoma, after treatment with a combination of anti‑angiogenic drugs and biological cytotoxic drugs, the mass was found to have become smaller than before, along with follow‑up treatment options, to provide a reference for clinical treatment decisions.